Correction to: Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study

Takafumi Soejima^{1,2} · Masaaki Shiohara³ · Yasushi Ishida⁴ · Masami Inoue⁵ · Akira Hayakawa⁶ · Atsushi Sato⁷ · Kiyoko Kamibepu^{1,2} · Yoshiko Atsuta^{8,9} · Takuya Yamashita¹⁰

Published online: 12 February 2021
© Japanese Society of Hematology 2021

Correction to: International Journal of Hematology
<https://doi.org/10.1007/s12185-020-03058-7>

In the original publication of the article, the Tables 1 and 2 were published incorrectly. The correct Tables 1 and 2 are given in this correction.

The original article can be found online at <https://doi.org/10.1007/s12185-020-03058-7>.

✉ Takafumi Soejima
tsoeji-ty@umin.ac.jp

¹ Department of Family Nursing, School of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

² Department of Health Quality and Outcome Research, Division of Nursing Systems, Global Nursing Research Center, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

³ Department of Pediatrics, Matsumoto Dental University Hospital, Shiojiri, Japan

⁴ Pediatric Medical Center, Ehime Prefectural Central Hospital, Matsuyama, Japan

⁵ Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan

⁶ Department of Palliative Care, Yodogawa Christian Hospital, Osaka, Japan

⁷ Department of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan

⁸ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

⁹ Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

¹⁰ Department of Hematology/Oncology, St. Luke's International Hospital, Tokyo, Japan

Table 1 Demographic and clinical characteristics in HCT survivors aged 8–15 years

	Auto-HCT (<i>n</i> = 38)		Allo-HCT (<i>n</i> = 150)		<i>p</i> ^a
	Median	IQR	Median	IQR	
Age at the time of the survey (year)	11.0	9.0–13.0	12.0	10.0–14.0	0.023
Age at HCT (year)	2.5	1.0–5.0	4.0	2.0–6.0	0.017
Time elapsed since HCT (year)	7.7	6.2–9.9	7.5	5.1–9.5	0.392
	<i>n</i>	%	<i>n</i>	%	<i>p</i> ^b
Female gender	15	40	60	40	1.000
Diagnosis					
ALL	0	0	47	31	<0.001
AML	0	0	25	17	
Hematopoietic dysfunction	0	0	29	19	
Lymphoma	1	3	1	1	
CML	0	0	3	2	
Myelodysplastic syndrome	1	3	10	7	
Hemophagocytic syndrome	0	0	7	5	
Primary immunodeficiency syndrome	0	0	19	13	
Congenital metabolic disorder	0	0	5	3	
Solid tumor	36	95	4	3	
Number of transplantation					
Once	35	92	137	91	1.000
More than twice	3	8	13	9	
Year at HCT					
–2000	1	3	5	3	1.000
2001–2005	16	42	63	42	
2006–	21	55	82	55	
Stem cell source					
Bone marrow	13	34	99	66	<0.001
Peripheral blood	25	66	8	5	
Cord blood	0	0	43	29	
Donor type					
Unrelated	–		90	60	
Conditioning regimen					
Myeloablative	–		81/108	75	0.009
Busulfan	0/33	0	21/133	16	
Cyclophosphamide	1/33	3	97/145	67	
Total body irradiation	5/33	15	73/139	53	
Administration of immunosuppressants for GVHD					
Steroid	–		14/132	11	
Cyclosporine	–		46/130	35	
Tacrolimus	–		94/146	64	
Methotrexate	–		123/145	85	
cGVHD symptoms					
Presence	–		63/148	43	
Skin	–		21/148	14	
Oral	–		13/148	9	
Eye	–		7/148	5	
Lung	–		6/148	4	
Gastrointestinal	–		3/148	2	
Liver	–		10/148	7	
Joint/muscle	–		9/148	6	
Genital	–		2/148	1	

ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, cGVHD chronic graft-versus-host disease, CML chronic myeloid leukemia, HCT hematopoietic stem cell transplantation, IQR interquartile range

^aMann–Whitney *U* test

^bFisher's exact test

Table 2 Demographic and clinical characteristics in HCT survivors aged ≥ 16 years

	Auto-HCT (<i>n</i> = 32)		Allo-HCT (<i>n</i> = 222)		<i>p</i> ^a
	Median	IQR	Median	IQR	
Age at the time of the survey (year)	20.5	18.0–29.0	20.0	18.0–24.0	0.330
Age at HCT (year)	9.0	4.0–14.8	10.0	7.0–13.0	0.415
Time elapsed since HCT (year)	13.8	10.9–16.7	10.6	7.4–14.5	0.005
	<i>n</i>	%	<i>n</i>	%	<i>p</i> ^b
Female gender	17	53	115	52	1.000
Diagnosis					
ALL	6	19	76/221	34	<0.001
AML	3	9	37/221	17	
Hematopoietic dysfunction	0	0	45/221	20	
Lymphoma	4	13	13/221	6	
CML	0	0	14/221	6	
Myelodysplastic syndrome	0	0	14/221	6	
Hemophagocytic syndrome	0	0	4/221	2	
Primary immunodeficiency syndrome	0	0	7/221	3	
Congenital metabolic disorder	0	0	8/221	4	
Solid tumor	19	59	3/221	1	
Number of transplantation					
Once	29	91	201	91	1.000
More than twice	3	9	21	10	
Year at HCT					
–2000	20	63	78	35	0.016
2001–2005	7	22	80	36	
2006–	5	16	64	29	
Stem cell source					
Bone marrow	10	31	179	81	<0.001
Peripheral blood	22	69	15	7	
Cord blood	0	0	28	13	
Donor type					
Unrelated	–		130	59	
Conditioning regimen					
Myeloablative	–		117/151	78	0.463
Busulfan	8/31	26	33/175	19	
Cyclophosphamide	4/31	13	133/203	66	
Total body irradiation	5/31	16	133/194	69	
Administration of immunosuppressants for GVHD					
Steroid	–		14/172	8	
Cyclosporine	–		89/178	50	
Tacrolimus	–		112/204	55	
Methotrexate	–		181/208	87	
cGVHD symptoms					
Presence	–		105/222	47	
Skin	–		39/222	18	
Oral	–		33/222	15	
Eye	–		27/222	12	
Lung	–		7/222	3	
Gastrointestinal	–		11/222	5	
Liver	–		25/222	11	
Joint/muscle	–		22/222	10	
Genital	–		13/222	6	

Table 2 Continued

ALL acute lymphoblastic leukemia, *AML* acute myeloid leukemia, *cGVHD* chronic graft-versus-host disease, *CML* chronic myeloid leukemia, *HCT* hematopoietic stem cell transplantation, *IQR* interquartile range

^aMann–Whitney *U* test

^bFisher’s exact test

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.